TrialInternational journal of molecular sciences2015

Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage.

Tetsuya Furukawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.